Fidelis Capital Partners LLC Raises Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Fidelis Capital Partners LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,494 shares of the biopharmaceutical company’s stock after purchasing an additional 268 shares during the period. Fidelis Capital Partners LLC’s holdings in Gilead Sciences were worth $392,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Farmers & Merchants Investments Inc. lifted its holdings in Gilead Sciences by 2.3% during the 3rd quarter. Farmers & Merchants Investments Inc. now owns 8,861 shares of the biopharmaceutical company’s stock worth $743,000 after buying an additional 200 shares during the last quarter. Cutter & CO Brokerage Inc. lifted its holdings in Gilead Sciences by 3.4% during the 3rd quarter. Cutter & CO Brokerage Inc. now owns 4,443 shares of the biopharmaceutical company’s stock worth $372,000 after buying an additional 147 shares during the last quarter. Fortitude Family Office LLC lifted its holdings in Gilead Sciences by 225.1% during the 3rd quarter. Fortitude Family Office LLC now owns 829 shares of the biopharmaceutical company’s stock worth $70,000 after buying an additional 574 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Gilead Sciences by 51.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 216,611 shares of the biopharmaceutical company’s stock worth $18,161,000 after buying an additional 73,443 shares during the last quarter. Finally, Pallas Capital Advisors LLC lifted its holdings in Gilead Sciences by 35.9% during the 3rd quarter. Pallas Capital Advisors LLC now owns 7,836 shares of the biopharmaceutical company’s stock worth $696,000 after buying an additional 2,069 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 36,847 shares of company stock valued at $3,033,340 over the last quarter. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

GILD opened at $88.29 on Thursday. The firm has a market cap of $110.00 billion, a PE ratio of 245.25, a P/E/G ratio of 3.07 and a beta of 0.18. The business has a fifty day simple moving average of $83.28 and a 200-day simple moving average of $73.86. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $89.74.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.61 by $0.40. The business had revenue of $6.95 billion during the quarter, compared to analysts’ expectations of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. As a group, equities analysts predict that Gilead Sciences, Inc. will post 3.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have commented on GILD. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Thursday, August 15th. BMO Capital Markets increased their price target on Gilead Sciences from $85.00 to $94.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price target on the stock in a research report on Monday, July 8th. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $70.00 price target on shares of Gilead Sciences in a research report on Monday, September 16th. Ten investment analysts have rated the stock with a hold rating, eleven have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $86.85.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.